Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLink™ Database

被引：0
|
作者：
Hoogwerf, Byron J.
Pelletier, Elise M.
Smith, Daniel B.
Best, Jennie H.
机构：
[1] Lilly USA LLC, Indianapolis, IN USA
[2] IMS Hlth, Watertown, MA USA
[3] IMS Healthcare, Watertown, MA USA
[4] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
CIRCULATION | 2010年 / 122卷 / 21期
关键词：
Cardiovascular disease prevention; Type; 2; Diabetes; Glucose;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13242
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Risk of Cardiovascular Events in Patients with Diabetes Treated with Exenatide or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLink™ Database
    Best, Jennie H.
    Pelletier, Elise M.
    Herman, William H.
    Hoogwerf, Byron J.
    DIABETES, 2010, 59 : A194 - A194
  • [2] Risk of cardiovascular events in patients with type 2 diabetes treated with exenatide or other glucose lowering therapies: a retrospective analysis of the LifeLink® database
    Best, J. H.
    Hoogwerf, B. J.
    Pelletier, E. M.
    Smith, D. B.
    Wenten, M.
    Hussein, M. A.
    DIABETOLOGIA, 2010, 53
  • [3] Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
    Best, Jennie H.
    Hoogwerf, Byron J.
    Herman, William H.
    Pelletier, Elise M.
    Smith, Daniel B.
    Wenten, Made
    Hussein, Mohamed A.
    DIABETES CARE, 2011, 34 (01) : 90 - 95
  • [4] Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
    Prattichizzo, Francesco
    La Sala, Lucia
    Ryden, Lars
    Marx, Nikolaus
    Ferrini, Marc
    Valensi, Paul
    Ceriello, Antonio
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (2_SUPPL) : 73 - 80
  • [5] RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES TREATED WITH EXENATIDE OR THIAZOLIDINEDIONES: A RETROSPECTIVE ANALYSIS OF THE PHARMETRICS DATABASE
    Best, J. H.
    Pelletier, E.
    Hoogwerf, B. J.
    Herman, W. H.
    DeYoung, M. B.
    Smith, D. B.
    Yushmanova, I
    Hussein, M.
    VALUE IN HEALTH, 2010, 13 (03) : A56 - A56
  • [6] COST OF ALL-CAUSE AND CARDIOVASCULAR DISEASE-RELATED HOSPITALIZATION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE BID, SULFONYLUREAS, OR INSULIN: A RETROSPECTIVE ANALYSIS OF THE LIFELINK DATABASE
    Best, J. H.
    Pelletier, E.
    Smith, D. B.
    VALUE IN HEALTH, 2011, 14 (03) : A95 - A95
  • [7] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    C. J. Currie
    C. D. Poole
    E. A. M. Gale
    Diabetologia, 2009, 52 : 1766 - 1777
  • [8] Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes
    Bonnet, F.
    Scheen, A. J.
    DIABETES & METABOLISM, 2017, 43 (04) : 299 - 313
  • [9] The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    Currie, C. J.
    Poole, C. D.
    Gale, E. A. M.
    DIABETOLOGIA, 2009, 52 (09) : 1766 - 1777
  • [10] Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
    Kalyani, Rita R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13): : 1248 - 1260
12345